Saccharomyces boulardii effects on gastrointestinal diseases
- PMID: 18780946
Saccharomyces boulardii effects on gastrointestinal diseases
Abstract
Health benefits attributed to probiotics have been described for decades. They include the treatment and the prevention of gastrointestinal diseases, vaginal and urinary infections and allergies. Saccharomyces boulardii, a species of yeast widely distributed, has been described as a biotherapeutic agent since several clinical trials displayed its beneficial effects in the prevention and the treatment of intestinal infections and in the maintenance of inflammatory bowel disease. All these diseases are characterized by acute diarrhoea. Administration of the yeast in combination or not with an antibiotherapy has shown to decrease significantly the duration and the frequency of diarrhoea. Experimental studies elucidated partially the molecular mechanisms triggered to improve the host health. The discovery of its anti-inflammatory and immuno-modulatory activities in correlation with the advances in the understanding of mucosal immunology opens a new field of perspectives in S. boulardii therapeutic applications.
Similar articles
-
Review article: yeast as probiotics -- Saccharomyces boulardii.Aliment Pharmacol Ther. 2007 Sep 15;26(6):767-78. doi: 10.1111/j.1365-2036.2007.03442.x. Aliment Pharmacol Ther. 2007. PMID: 17767461
-
Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease.Aliment Pharmacol Ther. 1998 Sep;12(9):807-22. doi: 10.1046/j.1365-2036.1998.00386.x. Aliment Pharmacol Ther. 1998. PMID: 9768523 Review.
-
Indications for the use of probiotics in gastrointestinal diseases.Dig Dis. 2011;29(6):574-87. doi: 10.1159/000332980. Epub 2011 Dec 12. Dig Dis. 2011. PMID: 22179214 Review.
-
Probiotics in gastroenterology: indications and future perspectives.Scand J Gastroenterol Suppl. 2003;(239):15-23. doi: 10.1080/00855920310002645. Scand J Gastroenterol Suppl. 2003. PMID: 14743878 Review.
-
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.World J Gastroenterol. 2019 May 14;25(18):2188-2203. doi: 10.3748/wjg.v25.i18.2188. World J Gastroenterol. 2019. PMID: 31143070 Free PMC article. Review.
Cited by
-
Anti-Cariogenic Effects of S. cerevisiae and S. boulardii in S. mutans-C. albicans Cross-Kingdom In Vitro Models.Pharmaceutics. 2024 Feb 1;16(2):215. doi: 10.3390/pharmaceutics16020215. Pharmaceutics. 2024. PMID: 38399269 Free PMC article.
-
The effects of probiotic Saccharomyces boulardii on the mental health, quality of life, fatigue, pain, and indices of inflammation and oxidative stress in patients with multiple sclerosis: study protocol for a double-blind randomized controlled clinical trial.Trials. 2019 Jun 24;20(1):379. doi: 10.1186/s13063-019-3454-9. Trials. 2019. PMID: 31234904 Free PMC article.
-
β-Galactomannan and Saccharomyces cerevisiae var. boulardii modulate the immune response against Salmonella enterica serovar Typhimurium in porcine intestinal epithelial and dendritic cells.Clin Vaccine Immunol. 2012 Mar;19(3):368-76. doi: 10.1128/CVI.05532-11. Epub 2012 Feb 1. Clin Vaccine Immunol. 2012. PMID: 22301691 Free PMC article.
-
Evaluation of the Probiotic Potential of Saccharomyces cerevisiae Strain (C41) Isolated from Tibicos by In Vitro Studies.Probiotics Antimicrob Proteins. 2019 Sep;11(3):794-800. doi: 10.1007/s12602-018-9471-2. Probiotics Antimicrob Proteins. 2019. PMID: 30238220
-
The first fungi: mode of delivery determines early life fungal colonization in the intestine of preterm infants.Microbiome Res Rep. 2022 Jan 28;1(1):7. doi: 10.20517/mrr.2021.03. eCollection 2022. Microbiome Res Rep. 2022. PMID: 38089064 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources